XOMA Co. (NASDAQ:XOMA - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for XOMA in a note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst D. Risinger anticipates that the biotechnology company will earn ($0.31) per share for the quarter. The consensus estimate for XOMA's current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA's Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.00 EPS and FY2029 earnings at $8.86 EPS.
XOMA (NASDAQ:XOMA - Get Free Report) last announced its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The firm had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.75 million.
A number of other equities analysts also recently weighed in on XOMA. HC Wainwright reaffirmed a "buy" rating and set a $104.00 target price on shares of XOMA in a research note on Wednesday. StockNews.com raised shares of XOMA from a "sell" rating to a "hold" rating in a research note on Friday.
Read Our Latest Report on XOMA
XOMA Stock Down 0.9 %
Shares of NASDAQ XOMA traded down $0.18 on Wednesday, reaching $20.88. 81,363 shares of the company's stock traded hands, compared to its average volume of 26,480. XOMA has a 12 month low of $19.92 and a 12 month high of $35.00. The business's 50 day simple moving average is $24.37 and its two-hundred day simple moving average is $27.13. The company has a market cap of $250.12 million, a price-to-earnings ratio of -6.00 and a beta of 1.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28.
Insider Buying and Selling at XOMA
In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.20% of the stock is owned by company insiders.
Institutional Investors Weigh In On XOMA
Several large investors have recently bought and sold shares of XOMA. Woodline Partners LP increased its holdings in XOMA by 63.9% in the 4th quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company's stock worth $4,107,000 after buying an additional 60,927 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in XOMA by 238.9% in the 4th quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company's stock worth $318,000 after buying an additional 8,522 shares in the last quarter. Barclays PLC increased its holdings in XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock worth $298,000 after buying an additional 8,447 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in XOMA in the 4th quarter worth about $206,000. Finally, Renaissance Technologies LLC grew its holdings in shares of XOMA by 89.8% in the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company's stock worth $423,000 after acquiring an additional 7,619 shares during the period. 95.92% of the stock is currently owned by institutional investors.
About XOMA
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
See Also
Before you consider XOMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XOMA wasn't on the list.
While XOMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
